D
Debabrata Mukherjee
Researcher at Texas Tech University Health Sciences Center at El Paso
Publications - 561
Citations - 43505
Debabrata Mukherjee is an academic researcher from Texas Tech University Health Sciences Center at El Paso. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 70, co-authored 514 publications receiving 38080 citations. Previous affiliations of Debabrata Mukherjee include Cleveland Clinic & University of Missouri.
Papers
More filters
Journal ArticleDOI
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Marco Roffi,Carlo Patrono,Jean-Philippe Collet,Christian Mueller,Marco Valgimigli,Felicita Andreotti,Jeroen J. Bax,Michael A. Borger,Carlos Brotons,Derek P. Chew,Baris Gencer,Gerd Hasenfuss,Keld Kjeldsen,Patrizio Lancellotti,Ulf Landmesser,Julinda Mehilli,Debabrata Mukherjee,Robert F. Storey,Stephan Windecker +18 more
TL;DR: The current guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation are based on the findings of the ESC Task Force on 12 March 2015.
Journal ArticleDOI
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Ezra A. Amsterdam,Nanette K. Wenger,Ralph G. Brindis,Donald E. Casey,Theodore G. Ganiats,David R. Holmes,Allan S. Jaffe,Hani Jneid,Rosemary F. Kelly,Michael C. Kontos,Glenn N. Levine,Philip R. Liebson,Debabrata Mukherjee,Eric D. Peterson,Marc S. Sabatine,Richard W. Smalling,Susan J. Zieman +16 more
TL;DR: In this article, Anderson et al. discuss the FAHA chair election process and discuss the state of the art in the field of cancer research. But they do not discuss the role of women in this process.
Journal ArticleDOI
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Glenn N. Levine,Eric R. Bates,James C. Blankenship,Steven R. Bailey,John A. Bittl,Bojan Cercek,Charles E. Chambers,Stephen G. Ellis,Robert A. Guyton,Steven M. Hollenberg,Umesh N. Khot,Richard A. Lange,Laura Mauri,Roxana Mehran,Issam Moussa,Debabrata Mukherjee,Brahmajee K. Nallamothu,Henry H. Ting,Alice K. Jacobs,Nancy M. Albert,Mark A. Creager,Steven M. Ettinger,Jonathan L. Halperin,Judith S. Hochman,Frederick G. Kushner,E. Magnus Ohman,William G. Stevenson,Clyde W. Yancy +27 more
TL;DR: Alice K. Jacobs, MD, FACC, FAHA, Chair Jeffrey L. Anderson, PhD, CCNS, CCRN, FAH, Chair-Elect - The first female FACC-FAHA board member to be elected in the history of the sport.
Journal ArticleDOI
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Glenn N. Levine,Eric R. Bates,James C. Blankenship,Steven R. Bailey,John A. Bittl,Bojan Cercek,Charles E. Chambers,Stephen G. Ellis,Robert A. Guyton,Steven M. Hollenberg,Umesh N. Khot,Richard A. Lange,Laura Mauri,Roxana Mehran,Issam Moussa,Debabrata Mukherjee,Brahmajee K. Nallamothu,Henry H. Ting,Alice K. Jacobs,Jeffrey L. Anderson,Nancy M. Albert,Mark A. Creager,Steven M. Ettinger,Jonathan L. Halperin,Judith S. Hochman,Frederick G. Kushner,E. Magnus Ohman,William G. Stevenson,Clyde W. Yancy +28 more
TL;DR: The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease as mentioned in this paper, and when properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can
Journal ArticleDOI
Risk of cardiovascular events associated with selective COX-2 inhibitors.
TL;DR: The results from VIGOR showed that the relative risk of developing a confirmed adjudicated thrombotic cardiovascular event with rofecoxib treatment compared with naproxen was higher than that in the placebo group of a recent meta-analysis of 23 407 patients in primary prevention trials.